Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CT-P63 in Healthy Subjects
NCT05017168Phase 1Completed
- Sponsor
- Celltrion
- Start
- Oct 2021
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing CT-P63 with Placebo (2 arms). Primary endpoint: Safety and tolerability of single ascending dose of CT-P63 up to 14 Days. Started Oct 2021; status: completed.
02
Drugs
CT-P63
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05017168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05017168.